BioCentury
ARTICLE | Clinical News

Revlimid lenalidomide: Phase IIIb started

May 5, 2014 7:00 AM UTC

Celgene disclosed in its 1Q14 earnings that it began the open-label, U.S. Phase IIIb MAGNIFY (NHL-008) trial to evaluate oral Revlimid plus IV Rituxan rituximab followed by maintenance therapy with either Revlimid or Rituxan monotherapy in about 500 patients with follicular, marginal zone or mantle cell lymphoma. In the induction phase, patients will receive 20 mg Revlimid once daily for the first 3 weeks of a 4-week cycle for up to 12 cycles and 375 mg/m 2 Rituxan every week for cycle 1 and on day 1 of each cycle thereafter. In the maintenance phase, patients will receive 10 mg Revlimid once daily for the first 3 weeks of each cycle or Rituxan on day 1 of each cycle for up to an additional 18 cycles.

Celgene markets Revlimid in nearly 70 countries, including the U.S. and EU countries, in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM) in patients who have received >=1 prior therapy. The drug is also approved in the U.S. and EU to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) with a 5q chromosomal deletion and in the U.S. for relapsed or refractory mantle cell lymphoma (MCL). ...